As of Wednesday, December 17, Estrella Immunopharma, Inc.’s ESLA share price has surged by 7.90%, which has investors ...

People aged 80 and older with a common type of lymphoma can take a half-dose of chemotherapy and be cured or significantly extend their survivorship with fewer toxic side effects, a new study shows.

Incyte has won European Commission expanded approval of its Minjuvi cancer drug for certain patients with one of the most-common subtypes of non-Hodgkin lymphoma.

Repay Holdings Corp (NASDAQ:RPAY) is one of the best multibagger penny stocks to buy right now. Repay Holdings (RPAY) holds a ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company ...

During a live event, Matthew Lunning, DO, discussed key factors that determine whether patients should receive CAR T-cell ...

At the recent American Society of Hematology (ASH) meeting, researchers presented early data from a phase II study evaluating ...

In this video, Brian T. Hill, MD, PhD, discusses promising results from a study examining the impact of acalabrutinib prior to frontline chemotherapy in patients with untreated diffuse large B-cell ...

In this video, Brian T. Hill, MD, PhD, discusses a study presented at ASH Annual Meeting and Exposition which assessed a triplet nonchemotherapy regimen in older and medically unfit patients with ...

Researchers sought to determine whether combination odronextamab plus CHOP would be safe and effective in patients with DLBCL.

Doctors may not need to avoid steroids before biopsy in patients with a common aggressive lymphoma, according to a new study.

Early ctDNA clearance, combined with complete response on PET-CT, correlates with prolonged progression-free survival. ctDNA testing is minimally invasive and can be conducted repeatedly, offering a ...